Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed

DISEASE CHARACTERISTICS: * Histologically confirmed unresectable non-small cell lung cancer with a growth pattern allowing access to the majority of tumor cells via the airway (e.g., bronchioloalveolar or papillary adenocarcinoma) PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 Life expectancy: * At least 12 weeks Hematopoietic: * Platelet count greater than 100,000/mm\^3 * Prothrombin time and partial thromboplastin time normal Hepatic: * Bilirubin less than 1.5 mg/dL Renal: * Creatinine less than 1.5 mg/dL Cardiovascular: * No New York Heart Association class III or IV heart disease Pulmonary: * Room air oxygen saturation greater than 90% * FEV1 greater than 1.0 L pCO2 less than 50 Other: * HIV negative * No active systemic viral, bacterial, or fungal infections requiring treatment * No concurrent illness requiring hospitalization or intravenous medication * Not pregnant or nursing * Effective contraception required of all fertile patients PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior adenovirus gene therapy * At least 2 weeks since any systemic biologic therapy including prior biologic response modifiers and recovered Chemotherapy: * At least 2 weeks since any prior systemic chemotherapy and recovered Endocrine therapy: * Recovered from any prior endocrine therapy Radiotherapy: * Recovered from any prior radiotherapy Surgery: * At least 2 weeks since any surgical procedure requiring anesthesia * At least 4 weeks since prior surgical resection of lung tissues Other: * No other concurrent therapy